An adjuvanted subunit SARS-CoV-2 spike protein vaccine provides protection against Covid-19 infection and transmission

Kairat Tabynov; Nurkeldi Turebekov; Meruert Babayeva; Gleb Fomin; Toktassyn Yerubayev; Tlektes Yespolov; Lei Li; Gourapura J. Renukaradhya; Nikolai Petrovsky; Kaissar Tabynov

doi:10.1038/s41541-022-00450-8

An adjuvanted subunit SARS-CoV-2 spike protein vaccine provides protection against Covid-19 infection and transmission

Kairat Tabynov
, Nurkeldi Turebekov
, Meruert Babayeva
, Gleb Fomin
, Toktassyn Yerubayev
, Tlektes Yespolov
, Lei Li
, Gourapura J. Renukaradhya
, Nikolai Petrovsky
, Kaissar Tabynov

College of Medicine and Public Health

Research output: Contribution to journal › Article › peer-review

25 Citations (Scopus)

79 Downloads (Pure)

Abstract

Recombinant protein approaches offer major promise for safe and effective vaccine prevention of SARS-CoV-2 infection. We developed a recombinant spike protein vaccine (called NARUVAX-C19) and characterized its ability when formulated with a nanoemulsion adjuvant to induce anti-spike antibody and T-cell responses and provide protection including against viral transmission in rodent. In mice, NARUVAX-C19 vaccine administered intramuscularly twice at 21-day interval elicited balanced Th1/Th2 humoral and T-cell responses with high titers of neutralizing antibodies against wild-type (D614G) and delta (B.1.617.2) variants. In Syrian hamsters, NARUVAX-C19 provided complete protection against wild-type (D614G) infection and prevented its transmission to naïve animals (n = 2/group) placed in the same cage as challenged animals (n = 6/group). The results contrasted with only weak protection seen with a monomeric spike receptor-binding domain (RBD) vaccine even when formulated with the same adjuvant. These encouraging results warrant the ongoing development of this COVID-19 vaccine candidate.

Original language	English
Article number	24
Number of pages	10
Journal	npj Vaccines
Volume	7
Issue number	1
DOIs	https://doi.org/10.1038/s41541-022-00450-8
Publication status	Published - 23 Feb 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Protein vaccines
Viral infection

Access to Document

10.1038/s41541-022-00450-8Licence: CC BY

Final published versionFinal published version, 3.01 MBLicence: CC BY

Cite this

@article{19d36ad6124743e2b59e13ddab1d6cbf,

title = "An adjuvanted subunit SARS-CoV-2 spike protein vaccine provides protection against Covid-19 infection and transmission",

abstract = "Recombinant protein approaches offer major promise for safe and effective vaccine prevention of SARS-CoV-2 infection. We developed a recombinant spike protein vaccine (called NARUVAX-C19) and characterized its ability when formulated with a nanoemulsion adjuvant to induce anti-spike antibody and T-cell responses and provide protection including against viral transmission in rodent. In mice, NARUVAX-C19 vaccine administered intramuscularly twice at 21-day interval elicited balanced Th1/Th2 humoral and T-cell responses with high titers of neutralizing antibodies against wild-type (D614G) and delta (B.1.617.2) variants. In Syrian hamsters, NARUVAX-C19 provided complete protection against wild-type (D614G) infection and prevented its transmission to na{\"i}ve animals (n = 2/group) placed in the same cage as challenged animals (n = 6/group). The results contrasted with only weak protection seen with a monomeric spike receptor-binding domain (RBD) vaccine even when formulated with the same adjuvant. These encouraging results warrant the ongoing development of this COVID-19 vaccine candidate.",

keywords = "Protein vaccines, Viral infection",

author = "Kairat Tabynov and Nurkeldi Turebekov and Meruert Babayeva and Gleb Fomin and Toktassyn Yerubayev and Tlektes Yespolov and Lei Li and Renukaradhya, \{Gourapura J.\} and Nikolai Petrovsky and Kaissar Tabynov",

year = "2022",

month = feb,

day = "23",

doi = "10.1038/s41541-022-00450-8",

language = "English",

volume = "7",

journal = "npj Vaccines",

issn = "2059-0105",

publisher = "Nature Research",

number = "1",

}

TY - JOUR

T1 - An adjuvanted subunit SARS-CoV-2 spike protein vaccine provides protection against Covid-19 infection and transmission

AU - Tabynov, Kairat

AU - Turebekov, Nurkeldi

AU - Babayeva, Meruert

AU - Fomin, Gleb

AU - Yerubayev, Toktassyn

AU - Yespolov, Tlektes

AU - Li, Lei

AU - Renukaradhya, Gourapura J.

AU - Petrovsky, Nikolai

AU - Tabynov, Kaissar

PY - 2022/2/23

Y1 - 2022/2/23

N2 - Recombinant protein approaches offer major promise for safe and effective vaccine prevention of SARS-CoV-2 infection. We developed a recombinant spike protein vaccine (called NARUVAX-C19) and characterized its ability when formulated with a nanoemulsion adjuvant to induce anti-spike antibody and T-cell responses and provide protection including against viral transmission in rodent. In mice, NARUVAX-C19 vaccine administered intramuscularly twice at 21-day interval elicited balanced Th1/Th2 humoral and T-cell responses with high titers of neutralizing antibodies against wild-type (D614G) and delta (B.1.617.2) variants. In Syrian hamsters, NARUVAX-C19 provided complete protection against wild-type (D614G) infection and prevented its transmission to naïve animals (n = 2/group) placed in the same cage as challenged animals (n = 6/group). The results contrasted with only weak protection seen with a monomeric spike receptor-binding domain (RBD) vaccine even when formulated with the same adjuvant. These encouraging results warrant the ongoing development of this COVID-19 vaccine candidate.

AB - Recombinant protein approaches offer major promise for safe and effective vaccine prevention of SARS-CoV-2 infection. We developed a recombinant spike protein vaccine (called NARUVAX-C19) and characterized its ability when formulated with a nanoemulsion adjuvant to induce anti-spike antibody and T-cell responses and provide protection including against viral transmission in rodent. In mice, NARUVAX-C19 vaccine administered intramuscularly twice at 21-day interval elicited balanced Th1/Th2 humoral and T-cell responses with high titers of neutralizing antibodies against wild-type (D614G) and delta (B.1.617.2) variants. In Syrian hamsters, NARUVAX-C19 provided complete protection against wild-type (D614G) infection and prevented its transmission to naïve animals (n = 2/group) placed in the same cage as challenged animals (n = 6/group). The results contrasted with only weak protection seen with a monomeric spike receptor-binding domain (RBD) vaccine even when formulated with the same adjuvant. These encouraging results warrant the ongoing development of this COVID-19 vaccine candidate.

KW - Protein vaccines

KW - Viral infection

UR - https://www.scopus.com/pages/publications/85125461457

U2 - 10.1038/s41541-022-00450-8

DO - 10.1038/s41541-022-00450-8

M3 - Article

AN - SCOPUS:85125461457

SN - 2059-0105

VL - 7

JO - npj Vaccines

JF - npj Vaccines

IS - 1

M1 - 24

ER -

An adjuvanted subunit SARS-CoV-2 spike protein vaccine provides protection against Covid-19 infection and transmission

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this